Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 2 | $0.18 | $0.18 | $0.18 |
Q2 2024 | 2 | $0.57 | $0.57 | $0.57 |
Q3 2024 | 2 | $0.28 | $0.29 | $0.29 |
Q4 2024 | 6 | $0.03 | $0.23 | $0.12 |
Q1 2025 | 3 | $0.39 | $0.44 | $0.43 |
Q2 2025 | 2 | $0.63 | $0.70 | $0.67 |
Q3 2025 | 2 | $0.63 | $0.71 | $0.68 |
Q4 2025 | 2 | $0.47 | $0.53 | $0.51 |
Q1 2026 | 1 | $0.71 | $0.80 | $0.77 |
Q2 2026 | 1 | $1.07 | $1.20 | $1.15 |
Q3 2026 | 1 | $0.90 | $1.01 | $0.97 |
Q4 2026 | 1 | $0.65 | $0.73 | $0.70 |
The Chemours Company last posted its earnings results on Monday, November 4th, 2024. The company reported $0.4 earnings per share for the quarter, topping analysts' consensus estimates of $0.32 by $0.08. The company had revenue of 1.50 B for the quarter and had revenue of 6.03 B for the year. The Chemours Company has generated $-2 earnings per share over the last year ($-1.6 diluted earnings per share) and currently has a price-to-earnings ratio of 38.44. The Chemours Company has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/04/2024 | Q3 2024 | $0.32 | -$0.18 | -0.5 | $1.44 B | $1.50 B |
08/01/2024 | Q2 2024 | $0.57 | $0.47 | -0.1 | $1.53 B | $1.54 B |
04/30/2024 | Q1 2024 | $0.18 | $0.35 | 0.17 | $1.35 B | |
03/27/2024 | Q4 2023 | $0.29 | -$0.17 | -0.46 | $1.36 B | |
10/27/2023 | Q3 2023 | $0.13 | $1.51 B | $1.49 B | ||
07/28/2023 | Q2 2023 | -$2.52 | $1.68 B | $1.64 B | ||
04/28/2023 | Q1 2023 | $0.97 | $1.54 B | |||
02/10/2023 | Q4 2022 | -$0.65 | $1.34 B | |||
10/26/2022 | Q3 2022 | $1.54 | $1.67 B | $1.78 B | ||
07/29/2022 | Q2 2022 | $1.29 | $1.84 B | $1.92 B | ||
05/03/2022 | Q1 2022 | $1.46 | $1.76 B | |||
02/11/2022 | Q4 2021 | $1.41 | $1.58 B | |||
11/05/2021 | Q3 2021 | $1.30 | $1.58 B | $1.68 B | ||
07/30/2021 | Q2 2021 | $0.40 | $1.53 B | $1.66 B | ||
05/04/2021 | Q1 2021 | $0.58 | $1.44 B | |||
02/12/2021 | Q4 2020 | $0.12 | $1.34 B | |||
11/04/2020 | Q3 2020 | $0.46 | $1.20 B | $1.23 B | ||
07/31/2020 | Q2 2020 | $0.15 | $1.09 B | $1.09 B | ||
05/06/2020 | Q1 2020 | $0.61 | $1.31 B | |||
02/14/2020 | Q4 2019 | -$1.94 | $1.35 B |
The Chemours Company has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
In the previous quarter, The Chemours Company (:CC) reported $0.4 earnings per share (EPS) to beat the analysts' consensus estimate of $0.32 by $0.08.
The conference call for The Chemours Company's latest earnings report can be listened to online.
The conference call transcript for The Chemours Company's latest earnings report can be read online.
The Chemours Company (:CC) has a recorded annual revenue of $6.03 B.
The Chemours Company (:CC) has a recorded net income of $6.03 B. The Chemours Company has generated $-1.6 earnings per share over the last four quarters.
The Chemours Company (:CC) has a price-to-earnings ratio of 38.44 and price/earnings-to-growth ratio is -0.97.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED